Roivant Sciences vs Whitehawk Therapeutics
Roivant Sciences reported revenue of $8 million in fiscal 2025, 1.2 times Whitehawk Therapeutics' $7 million in fiscal 2025. Roivant Sciences' revenue fell 71.6% in its latest year, and Whitehawk Therapeutics' fell 72.5%. Roivant Sciences had an operating margin of -6235.7%, against -1601.1% at Whitehawk Therapeutics. Free cash flow was −$759 million at Roivant Sciences and −$98 million at Whitehawk Therapeutics. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.
Side by side
| Roivant Sciences | Whitehawk Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Mar 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $8M | $7M |
| Revenue growth | −71.6% | −72.5% |
| Revenue growth a year, last 5 years | −19.0% | −12.7% |
| Gross margin | — | 89.4% |
| Operating margin | −6,235.7% | −1,601.1% |
| Net margin | −3,629.2% | −288.3% |
| Free cash flow | −$759M | −$98M |
| Free cash flow margin | −9,183.5% | −1,371.4% |
| Return on capital | −62.6% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −4.3% | 129.0% |
| Last close | $38.96 | $3.12 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $602.3 million | sold $2.6 million |
| Piotroski F-score | 1 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Roivant SciencesWhitehawk Therapeutics
Operating margin
Percent of revenue
Roivant SciencesWhitehawk Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Roivant SciencesWhitehawk Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Roivant Sciences and Whitehawk Therapeutics pages.